Sclérodermie
Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon X, Chene G, Taïeb A. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br JDermatol. 2012 Nov;167(5):1138-44
Pelade
Droitcourt C, Milpied B, Ezzedine K, Hubiche T, Belin E, Akpadjan F, Taïeb A, Seneschal J. Interest of high-dose pulse corticosteroid therapy combined with ethotrexate for severe alopecia areata: a retrospective case series. Dermatology. 2012;224(4):369-73.
Vitiligo
Gey A, Diallo A, Seneschal J, Léauté-Labrèze C, Jouary T, Taieb A, Ezzedine K. Auto-immune thyroid stigma in vitiligo: multivariate analysis indicates intricated pathomechanisms. Br J Dermatol. 2012 Dec 18. doi: 10.1111/bjd.12166. [Epub ahead of print]
Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M; the writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum
consensus. Br J Dermatol. 2013 Jan;168(1):5-19.
Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T,Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L,Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A; Vitiligo Global Issue
Consensus Conference Panelists. Revised classification/nomenclature of vitiligoand related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May;25(3):E1-13
Ezzedine K, Diallo A, Léauté-Labrèze C, Seneschal J, Boniface K, Cario-André M, Prey S, Ballanger F, Boralevi F, Jouary T, Mossalayi D, Taieb A. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis
association in pre-pubertal onset vitiligo. Br J Dermatol. 2012 Sep;167(3):490-5.
Ezzedine K, Diallo A, Léauté-Labrèze C, Seneschal J, Mossalayi D, AlGhamdi K, Prey S, Bouchtnei S, Cario-André M, Boralevi F, Jouary T, Taieb A. Halo nevi association in nonsegmental vitiligo affects age at onset and depigmentation
pattern. Arch Dermatol. 2012 Apr;148(4):497-502.
Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 2012 Jan;25(1):9-13.
Ezzedine K, Diallo A, Léauté-Labrèze C, Séneschal J, Prey S, Ballanger F, Alghamdi K, Cario-André M, Jouary T, Gauthier Y, Taieb A. Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup
of segmental vitiligo. Br J Dermatol. 2012 Mar;166(3):539-44.
Toxidermies
Seneschal J, Milpied B, Taieb A. Cutaneous drug eruptions associated with the use of biologics and cutaneous drug eruptions mimicking specific skin diseases. Chem Immunol Allergy. 2012;97:203-16. doi: 10.1159/000335633. Epub 2012 May 3. PubMed PMID: 22613864.
Seneschal J, Guillet S, Ezzedine K, Taïeb A, Milpied B. Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. Dermatology.
2012;224(2):115-9
Dermatite atopique/ Ichtyose vulgaire
Ezzedine K, Droitcourt C, Ged C, Diallo A, Hubiche T, de Verneuil H, Boralevi F, Taïeb A. Usefulness of a global clinical ichthyosis vulgaris scoring system for predicting common FLG null mutations in an adult caucasian population. Br J
Dermatol. 2012 Nov;167(5):1165-9.
Dermatologie pédiatrique/ hémangiomes et malformations vasculaires
Prey S, Haberstroh G, Vergier B, Taïeb A, Wassef M, Ezzedine K, Léauté-Labrèze C. Successful treatment of intravascular papillary endothelial hyperplasia (IPEH) by the beta-adrenergic antagonist nebivolol. Br J Dermatol.
2012 May;166(5):1147-9.
Milpied B, Ezzedine K, Ohayon-Courtès C, Genillier-Foin N, Perromat M, Taieb A, Léauté-Labrèze C. Are post-vaccinal persistent itching nodules related to the use of local anaesthetic patches? A hypothesis to be confirmed. Contact
Dermatitis. 2012 Jun;66(6):343-4.
Moehrle M, Léauté-Labrèze C, Schmidt V, Röcken M, Poets CF, Goelz R. Topical Timolol for Small Hemangiomas of Infancy. Pediatr Dermatol. 2012 Apr 4. doi:10.1111/j.1525-1470.2012.01723.x. [Epub ahead of print]
Cante V, Pham-Ledard A, Imbert E, Ezzedine K, Léauté-Labrèze C. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed. 2012 Mar;97(2):F155-6
Thoumazet F, Léauté-Labrèze C, Colin J, Mortemousque B. Efficacy of systemic propranolol for severe infantile haemangioma of the orbit and eyelid: a case study of eight patients. Br J Ophthalmol. 2012 Mar;96(3):370-4.
Gelmetti C, Boralevi F, Seité S, Grimalt R, Humbert P, Luger T, Stalder JF, Taïeb A, Tennstedt D, Garcia Diaz R, Rougier A. Quality of life of parents living with a child suffering from atopic dermatitis before and after a 3-month treatment with an emollient. Pediatr Dermatol. 2012 Nov-Dec;29(6):714-8
Castela E, Chiaverini C, Boralevi F, Hugues R, Lacour JP. Papular, profuse, and precocious keratosis pilaris. Pediatr Dermatol. 2012 May-Jun;29(3):285-8.
Cancérologie cutanée-mélanome
Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, Leccia MT, Landthaler M, Garbe C, Sassolas B, Herbst RA, Guillot B, Chene G, Pehamberger H. Adjuvant therapy with pegylated interferon alfa-2b (36months) versus low-dose interferon alfa-2b (18months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013 Jan;49(1):166-74.
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65
Inserm U1035
Ricard AS, Pain C, Daubos A, Ezzedine K, Lamrissi-Garcia I, Bibeyran A, Guyonnet-Dupérat V, Taieb A, Cario-André M. Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin. Exp Dermatol. 2012 Jun;21(6):411-6.
Rezvani HR, Ali N, Serrano-Sanchez M, Dubus P, Varon C, Ged C, Pain C, Cario-André M, Seneschal J, Taïeb A, de Verneuil H, Mazurier F. Loss of epidermal hypoxia-inducible factor-1α accelerates epidermal aging and affects
re-epithelialization in human and mouse. J Cell Sci. 2011 Dec 15;124(Pt24):4172-83.
Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, Fieschi C, Lim A, Abhyankar A, Gineau L, Mueller-Fleckenstein I, Schmidt M, Taieb A, Krueger J, Abel L, Tangye SG, Orth G, Williams DA, Casanova JL, Jouanguy E. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012 Sep 4;122(9):3239-47.
Dell'anna ML, Cario-André M, Bellei B, Taieb A, Picardo M. In vitro research on vitiligo: strategies, principles, methodological options and common pitfalls. Exp Dermatol. 2012 Jul;21(7):490-6
Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, Cole JB, Gowan K,Holland PJ, Bennett DC, Luiten RM, Wolkerstorfer A, van der Veen JP, Hartmann A, Eichner S, Schuler G, van Geel N, Lambert J, Kemp EH, Gawkrodger DJ, Weetman AP, Taïeb A, Jouary T, Ezzedine K, Wallace MR, McCormack WT, Picardo M, Leone G, Overbeck A, Silverberg NB, Spritz RA. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet. 2012 May6;44(6):676-80.
Publications majeures 2011
|
